CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
ranibizumab 0.5mg +1 moredrug
Likely dose
ranibizumab 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01471691
NCT01471691Phase 2Completed
CompareCT.gov

Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)

Hanscom, Thomas, M.D.·interventional·Posted Nov 16, 2011·Updated Apr 29, 2015

In Brief

A Phase 2 clinical trial evaluating ranibizumab 0.5mg and ranibizumab 1.0mg for Branch Retinal Vein Occlusion and 2 related conditions. Completed, enrolled 14 participants across 4 sites.

Detailed Summary

This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including bevacizumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBranch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 16, 2011
Enrollment StartNov 1, 2011
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.6 years ago

Interventions

ranibizumab 0.5mgdrug

Standard dose

ranibizumab 1.0mgdrug

High dose